$ELDN
Eledon Pharmaceuticals, Inc.

2018 Q4 Form 10-Q Financial Statement

#000156459018028982 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.840M $1.850M $2.450M
YoY Change 14.29% -24.49% -22.22%
% of Gross Profit
Research & Development $2.740M $1.651M $517.0K
YoY Change 459.18% 219.34% -91.61%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.580M $3.499M $2.965M
YoY Change 117.06% 18.01% -68.15%
Operating Profit -$3.499M -$2.965M
YoY Change 18.01% -68.15%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $3.000K -$5.000K
YoY Change -100.0% -160.0%
Pretax Income -$4.570M -$3.500M -$2.970M
YoY Change 116.59% 17.85% -67.96%
Income Tax
% Of Pretax Income
Net Earnings -$4.570M -$3.496M -$2.970M
YoY Change 116.59% 17.71% -67.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.788M -$6.731M -$7.615M
COMMON SHARES
Basic Shares Outstanding 9.422M 9.422M 6.943M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.00M $16.30M $19.10M
YoY Change -24.42% -14.66% -44.96%
Cash & Equivalents $12.97M $16.32M $19.09M
Short-Term Investments
Other Short-Term Assets $36.00K $15.00K $1.900M
YoY Change 100.0% -99.21% 18.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.28M $17.11M $21.00M
YoY Change -24.86% -18.52% -42.2%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K $17.00K $0.00
YoY Change -44.0% -100.0%
Goodwill $1.867M $1.867M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $869.0K $934.0K $100.0K
YoY Change 834.0% -66.67%
Total Long-Term Assets $2.750M $2.818M $2.000M
YoY Change 45.35% 40.9% 416.8%
TOTAL ASSETS
Total Short-Term Assets $14.28M $17.11M $21.00M
Total Long-Term Assets $2.750M $2.818M $2.000M
Total Assets $17.03M $19.93M $23.00M
YoY Change -18.5% -13.36% -37.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $689.0K $751.0K $200.0K
YoY Change 64.83% 275.5% -77.43%
Accrued Expenses $1.800M $900.0K $2.100M
YoY Change 80.0% -57.14% -61.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.534M $1.600M $2.306M
YoY Change 81.0% -30.62% -63.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $100.0K
YoY Change -100.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $94.00K
YoY Change -100.0% -21.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.534M $1.600M $2.306M
Total Long-Term Liabilities $0.00 $0.00 $94.00K
Total Liabilities $2.534M $1.603M $2.400M
YoY Change 75.97% -33.21% -62.87%
SHAREHOLDERS EQUITY
Retained Earnings -$41.57M -$37.00M
YoY Change 51.13%
Common Stock $56.06M $55.32M $7.000K
YoY Change 19.39% 790214.29% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.49M $18.33M $20.60M
YoY Change
Total Liabilities & Shareholders Equity $17.03M $19.93M $23.00M
YoY Change -18.5% -13.36% -37.37%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.570M -$3.496M -$2.970M
YoY Change 116.59% 17.71% -67.96%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.350M -$2.930M -$3.420M
YoY Change 28.35% -14.33% -62.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 70.00K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.350M -2.930M -3.420M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 70.00K 0.000
Net Change In Cash -3.350M -2.860M -3.420M
YoY Change 80.11% -16.37% -152.78%
FREE CASH FLOW
Cash From Operating Activities -$3.350M -$2.930M -$3.420M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
668000
CY2017Q4 us-gaap Liabilities
Liabilities
1440000
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9422143
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
19452000
dei Entity Small Business
EntitySmallBusiness
true
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
70000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1697000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
19000000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
CY2017Q4 us-gaap Goodwill
Goodwill
1867000
CY2018Q3 us-gaap Assets
Assets
19928000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
751000
CY2018Q3 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
90000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
46951000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19928000
us-gaap Net Income Loss
NetIncomeLoss
-11006000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9420039
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6943058
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
23000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
163000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8540000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12330000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
23250000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
8000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23258000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7490000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3119000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7561000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7119000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-979000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18047000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17303000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1117000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16324000
nvus Conversion Of Promissory Notes And Interest To Common Stock
ConversionOfPromissoryNotesAndInterestToCommonStock
3447000
nvus Conversion Of Contingently Issuable Shares To Common Stock
ConversionOfContingentlyIssuableSharesToCommonStock
291000
us-gaap Stock Issued1
StockIssued1
23375000
nvus Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
27000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q3 us-gaap Goodwill
Goodwill
1867000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
934000
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q3 us-gaap Cash
Cash
16324000
CY2017Q4 us-gaap Cash
Cash
17233000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
786000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
418000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
17110000
CY2018Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
762000
CY2017Q4 us-gaap Assets
Assets
20892000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
354000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5406000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
3499000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2448000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9483000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11016000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2018Q3 us-gaap Liabilities
Liabilities
1603000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-3496000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2970000
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
18325000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55313000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36997000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27506000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9422143
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9422143
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1529000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1848000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9487000
us-gaap Operating Expenses
OperatingExpenses
11016000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3499000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2965000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20892000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7110414
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1651000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
2965000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7110414
us-gaap Operating Expenses
OperatingExpenses
9483000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
517000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4077000
us-gaap Net Income Loss
NetIncomeLoss
-9491000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8864895
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3845258
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
18000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
803000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
386000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-31000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
761000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-998000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19164000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
3072000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2947000
nvus Fair Value Of Assets Acquired And Liabilities Assumed In Merger
FairValueOfAssetsAcquiredAndLiabilitiesAssumedInMerger
125000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to stock-based compensation, accruals for liabilities, carrying value of goodwill, and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements. </p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.36%;">Certain reclassifications of prior period amounts have been made to conform to the current period presentation.</p></div>
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
840115
CY2018Q3 nvus Working Capital
WorkingCapital
15500000
nvus Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2018Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
328000
nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
2666000
CY2018Q3 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-3496000
CY2017Q3 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-2970000
nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-9491000
nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-8668000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
975876
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
930831
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
710898
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
462012
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q3 nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
517000
nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
1988000
CY2017Q3 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
2270000
nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
7744000
CY2017Q3 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
2787000
nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
9732000
CY2017Q3 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-2787000
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-9732000
CY2017Q3 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
-5000
nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
50000
CY2017Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2792000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-9682000
CY2017Q3 nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-0.40
nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-1.39
CY2017Q3 nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6943058
nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6943058
CY2018Q3 us-gaap Prepaid Insurance
PrepaidInsurance
480000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1518000
CY2018Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
291000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
161000
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
15000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18000
CY2018Q3 nvus Accrued Clinical Current
AccruedClinicalCurrent
350000
CY2017Q4 nvus Accrued Clinical Current
AccruedClinicalCurrent
85000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
158000
CY2018Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
131000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
111000
CY2018Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
52000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
42000
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
252000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
126000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
455000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
46000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
187000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
195000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
152000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
580000
nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2017 nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0
CY2018Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2018Q3 nvus Contingent Liability
ContingentLiability
0
CY2017 nvus Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q3 nvus Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2017Q4 nvus Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0

Files In Submission

Name View Source Status
0001564590-18-028982-index-headers.html Edgar Link pending
0001564590-18-028982-index.html Edgar Link pending
0001564590-18-028982.txt Edgar Link pending
0001564590-18-028982-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nvus-10q_20180930.htm Edgar Link pending
nvus-20180930.xml Edgar Link completed
nvus-20180930.xsd Edgar Link pending
nvus-20180930_cal.xml Edgar Link unprocessable
nvus-20180930_def.xml Edgar Link unprocessable
nvus-20180930_lab.xml Edgar Link unprocessable
nvus-20180930_pre.xml Edgar Link unprocessable
nvus-ex311_11.htm Edgar Link pending
nvus-ex312_9.htm Edgar Link pending
nvus-ex321_7.htm Edgar Link pending
nvus-ex322_12.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending